- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05351190
Community Glucose Monitoring Project (CMGProject)
Community Glucose Monitoring (CGM) Project
The investigators believe that addition of real time continuous glucose monitoring (RT-CGM) improves glycemic outcome in patients with Type 2 diabetes compared to self-monitored blood glucose (SMBG), for patients who are not at target A1C regardless of treatment modality.
The investigators aims to assess glycemic and quality of life (QoL) benefits of adding and using RT-CGM patients with Type 2 Diabetes Mellitus (T2DM), not at their A1C goal and relying on SMBG for diabetes-management decisions.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Prescreened and eligible subjects will obtain CGM and basic CGM education upon enrollment.
They will initially be given three months of CGM supplies and return to the study center every 3 months for more supplies. In addition, baseline data and labs will be collected at visits.
All subjects will return to the clinic after every three months for assessment and assignment of three more months of CGM supplies. This will repeat for a 12 month period.
Patient reported outcome (PRO) measurements will be obtained at the beginning and end of the study.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Findlay, Ohio, United States, 45840
- Hancock County Health Department
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 years or older
- Diagnosis of T2DM
- Followed regularly by a physician with at least 2 office visits in last year as documented by clinical history
- Sub-optimal glycemic control, defined as persistent hyperglycemia, confirmed initially by historical or local (POC or site's lab) A1C of ≥7.7% NOTE: Use of a historical local A1C test must be within 1 month of study entry.
- Desire to lower A1C such as a goal of 7%
- Stable control of diabetes, as determined per investigator assessment
- Willing to wear a CGM
Exclusion Criteria:
- Use of personal RT-CGM 3 months prior to study entry (professional CGM use is allowed, whether it was blinded or un-blinded)
- Current or anticipated acute uses of glucocorticoids (oral, injectable, or IV), that will affect glycemic control and impact A1C - such as frequent steroid bursts required for inflammatory arthritis or inflammatory bowel disease, recurrent lumbar epidural steroid injections, etc. (Long-term stable glucocorticoid doses are allowed, such as when used for the treatment of rheumatoid arthritis or Addison's disease).
- Pregnancy (as demonstrated by a positive test at study entry screening) or are planning to become pregnant during the study
- Medical conditions that, per investigator determination, make it inappropriate or unsafe to target an A1C of <7%, such as, but not limited to, recent cardio- or cerebro- vascular disease, malignancy, severe recurrent hypoglycemia, or cognitive decline
- History of visual impairment which would hinder subject's participation in the study and perform all study procedures safely, as determined by investigator
- History of psychiatric, psychological disorder, or psycho-social issues that could limit adherence to the required study tasks
- Renal disease defined as estimated Glomerular Filtration Rate (eGFR) <45)
- Extensive skin changes/disease that preclude wearing the sensor on normal skin (e.g. extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis)
- Known allergy to medical-grade adhesives
- Current participation in another investigational study (must have completed any previous studies at least 30 days prior to being enrolled in this study)
- Currently abusing illicit drugs, alcohol, or prescription drugs
- Any condition per investigator assessment, that could impact reliability of the A1C measurement, such as (but not limited to) hemoglobinopathy, hemolytic anemia, chronic liver disease; chronic GI blood loss, recent red blood cell transfusion or erythropoietin administration within 3 months prior to screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Treatment Arm
All participants will be given a rtCGM (Dexcom G6) to assess their glycemic control.
|
rtCGM to be worn by user continuously for the duration of the 12 month study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
A1c
Time Frame: Baseline to 3 months
|
Record Changes in HgbA1c
|
Baseline to 3 months
|
A1c
Time Frame: Baseline to 6 months
|
Record Changes in HgbA1c
|
Baseline to 6 months
|
A1c
Time Frame: Baseline to 9 months
|
Record Changes in HgbA1c
|
Baseline to 9 months
|
A1c
Time Frame: Baseline to 12 months
|
Record Changes in HgbA1c
|
Baseline to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weight
Time Frame: Baseline to 3 months
|
Record Changes
|
Baseline to 3 months
|
Weight
Time Frame: Baseline to 6 months
|
Record Changes
|
Baseline to 6 months
|
Weight
Time Frame: Baseline to 9 months
|
Record Changes
|
Baseline to 9 months
|
Weight
Time Frame: Baseline to 12 months
|
Record Changes
|
Baseline to 12 months
|
BMI
Time Frame: Baseline to 3 months
|
Record Changes
|
Baseline to 3 months
|
BMI
Time Frame: Baseline to 6 months
|
Record Changes
|
Baseline to 6 months
|
BMI
Time Frame: Baseline to 9 months
|
Record Changes
|
Baseline to 9 months
|
BMI
Time Frame: Baseline to 12 months
|
Record Changes
|
Baseline to 12 months
|
Quality of Life - GMSS T2DM Version
Time Frame: Baseline to 6 months
|
Record Changes in QoL
|
Baseline to 6 months
|
Quality of Life - GMSS T2DM Version
Time Frame: Baseline to 12 months
|
Record Changes in QoL
|
Baseline to 12 months
|
Percent Time in Range (70-180 mg/dl)
Time Frame: Baseline to 3 months
|
Record Changes
|
Baseline to 3 months
|
Percent Time in Range (70-180 mg/dl)
Time Frame: Baseline to 6 months
|
Record Changes
|
Baseline to 6 months
|
Percent Time in Range (70-180 mg/dl)
Time Frame: Baseline to 9 months
|
Record Changes
|
Baseline to 9 months
|
Percent Time in Range (70-180 mg/dl)
Time Frame: Baseline to 12 months
|
Record Changes
|
Baseline to 12 months
|
Percent Time in Hypoglycemia (<70 mg/dl)
Time Frame: Baseline to 3 months
|
Record Changes
|
Baseline to 3 months
|
Percent Time in Hypoglycemia (<70 mg/dl)
Time Frame: Baseline to 6 months
|
Record Changes
|
Baseline to 6 months
|
Percent Time in Hypoglycemia (<70 mg/dl)
Time Frame: Baseline to 9 months
|
Record Changes
|
Baseline to 9 months
|
Percent Time in Hypoglycemia (<70 mg/dl)
Time Frame: Baseline to 12 months
|
Record Changes
|
Baseline to 12 months
|
Percent Time in Hyperglycemia (>180 mg/dl)
Time Frame: Baseline to 3 months
|
Record Changes
|
Baseline to 3 months
|
Percent Time in Hyperglycemia (>180 mg/dl)
Time Frame: Baseline to 6 months
|
Record Changes
|
Baseline to 6 months
|
Percent Time in Hyperglycemia (>180 mg/dl)
Time Frame: Baseline to 9 months
|
Record Changes
|
Baseline to 9 months
|
Percent Time in Hyperglycemia (>180 mg/dl)
Time Frame: Baseline to 12 months
|
Record Changes
|
Baseline to 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Thomas Grace, MD, Hancock County Health Department
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- IIS-2021-169
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Dexcom G6 CGM
-
Medical University of GdanskNot yet recruitingHyperglycemia | Infections | Hypoglycemia | Surgical Site Infection | PeritonitisPoland
-
Columbia UniversityDexCom, Inc.Not yet recruitingDiabetic KetoacidosisUnited States
-
Oregon Health and Science UniversityDexCom, Inc.CompletedExercise | Type 1 Diabetes Mellitus | CGM | MDIUnited States
-
Universitaire Ziekenhuizen KU LeuvenDexCom, Inc.CompletedType 1 Diabetes MellitusBelgium
-
Nicole Ehrhardt, MDDexCom, Inc.CompletedObesity | Diabetes Mellitus, Type 2 | PreDiabetesUnited States
-
Emory UniversityCompletedEnd Stage Kidney DiseaseUnited States
-
Woman'sDexCom, Inc.CompletedGestational Diabetes Mellitus in PregnancyUnited States
-
Aalborg University HospitalAalborg University; Steno Diabetes Center NordjyllandCompletedType1diabetes | Hemodialysis | Type2DiabetesDenmark
-
University of MinnesotaRecruitingHyperglycemia | Very Low Birth Weight Infant | Very Preterm Maturity of InfantUnited States
-
Mayo ClinicSuspendedDiabetes MellitusUnited States